Evidence map›Paper›PMID 35745773›Full record

ArticlePharmaceutics2022

Cu

Yanyan Zhang, Jiadong Lou, Gareth R Williams, Yuhan Ye, Dandan Ren, Anhua Shi, Junzi Wu, Wenling Chen, Li-Min Zhu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Nanotechnology for the Diagnosis and Treatment of Liver Cancer.International journal of nanomedicine · 2024
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yanyan ZhangCollege of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai 201620, China.
Jiadong LouCollege of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai 201620, China.
Gareth R WilliamsUCL School of Pharmacy, University College London, 29-39 Brunswick Square, London WC1N 1AX, UK.ORCID 0000-0002-3066-2860
Yuhan YeCollege of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai 201620, China.
Dandan RenCollege of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai 201620, China.
Anhua ShiThe Key Laboratory of Microcosmic Syndrome Differentiation, Education Department of Yunnan, Yunnan University of Chinese Medicine, Kunming 650500, China.
Junzi WuThe Key Laboratory of Microcosmic Syndrome Differentiation, Education Department of Yunnan, Yunnan University of Chinese Medicine, Kunming 650500, China.ORCID 0000-0002-2976-5299
Wenling ChenSchool of Clinical Medicine, Yunnan University of Chinese Medicine, Kunming 650500, China.
Li-Min ZhuCollege of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai 201620, China.

Funding

the Biomedical Textile Materials "111 Project" of the Ministry of Education of China B07024the Science and Technology Commission of Shanghai Municipality 16410723700
6 · The paper itself

Abstract

In this study, a pH-responsive controlled-release mesoporous silica nanoparticle (MSN) formulation was developed. The MSNs were functionalized with a histidine (His)-tagged targeting peptide (B3int) through an amide bond, and loaded with an anticancer drug (cisplatin (CP)) and a lysosomal destabilization mediator (chloroquine (CQ)). Cu

Indexed as

chelationgatekeepermesoporous silica nanoparticlessynergistic treatment

Identifiers

PMID35745773
PMCPMC9229203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.